Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

606 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
Narayan P, Osgood CL, Singh H, Chiu HJ, Ricks TK, Chiu Yuen Chow E, Qiu J, Song P, Yu J, Namuswe F, Guiterrez-Lugo M, Hou S, Pierce WF, Goldberg KB, Tang S, Amiri-Kordestani L, Theoret MR, Pazdur R, Beaver JA. Narayan P, et al. Among authors: pazdur r. Clin Cancer Res. 2021 Aug 15;27(16):4478-4485. doi: 10.1158/1078-0432.CCR-20-4557. Epub 2021 Mar 22. Clin Cancer Res. 2021. PMID: 33753456 Free PMC article. Clinical Trial.
FDA drug approval summaries: fulvestrant.
Bross PF, Cohen MH, Williams GA, Pazdur R. Bross PF, et al. Among authors: pazdur r. Oncologist. 2002;7(6):477-80. doi: 10.1634/theoncologist.7-6-477. Oncologist. 2002. PMID: 12490735 Free article.
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Oncologist. 2003;8(4):303-6. doi: 10.1634/theoncologist.8-4-303. Oncologist. 2003. PMID: 12897327 Free article. Clinical Trial.
606 results